与此同时,该公司在周二收盘后表示,Idera 不再招募患者进入 tilsotolimod 与 BMS的 Yervoy 和 ...查看全文
$井寺制药(IDRA)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2019-06-06 AccNo: 0001144204-19-030116 Size: 107 KB 网页链接
$井寺制药(IDRA)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2019-05-02 AccNo: 0001558370-19-003862 Size: 5 MB 网页链接
$井寺制药(IDRA)$ 8-K - Current report Filed: 2019-05-02 AccNo: 0001104659-19-026493 Size: 117 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$井寺制药(IDRA)$ DEF 14A - Other definitive proxy statements Filed: 2019-04-25 AccNo: 0001047469-19-002568 Size: 1 MB 网页链接
$井寺制药(IDRA)$ 8-K - Current report Filed: 2019-04-10 AccNo: 0001104659-19-020569 Size: 27 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$井寺制药(IDRA)$ 8-K - Current report Filed: 2019-03-13 AccNo: 0001104659-19-014475 Size: 23 KBItem 1.01: Entry into a Material Definitive Agreement 网页链接
$井寺制药(IDRA)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-03-06 AccNo: 0001104659-19-013132 Size: 347 KB 网页链接
$井寺制药(IDRA)$ 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2019-03-06 AccNo: 0001558370-19-001585 Size: 12 MB 网页链接
$井寺制药(IDRA)$ 8-K - Current report Filed: 2019-03-06 AccNo: 0001104659-19-013146 Size: 139 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$井寺制药(IDRA)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-08 AccNo: 0000215457-19-006740 Size: 13 KB 网页链接